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Mechanism of the decreased renal blood flow in the potassium-depleted
conscious rat. Although chronic potassium deficiency is a common
clinical problem, the hemodynamic consequences of chronic sustained
potassium depletion have not been clearly delineated. In this study, the
hemodynamic consequences of chronic potassium depletion were eval-
uated in the conscious rat. Potassium-depleted rats had a decrease in
mean arterial pressure which was caused by a decrease in systemic
vascular resistance. In association with these changes in systemic
hemodynamics, renal blood flow (RBF) was also decreased. The
decreased renal blood flow was caused by an increased renal vascular
resistance (RVR). Because plasma renin activity was increased the role
of angiotensin II as a renal vasoconstrictor was evaluated by utilizing
two angiotensin antagonists. Although the administration of saralasin to
potassium-depleted rats did not alter systemic hemodynamics, RVR
was decreased and RBF was increased. Similar results were obtained
with the converting enzyme inhibitor teprotide. Because products of
endoperoxide metabolism may cause renal vasoconstriction, the role of
prostaglandins and thromboxanes as renal vasoconstrictors were evalu-
ated by utilizing cyclo-oxygenase and thromboxane synthetase inhibi-
tors. None of these agents altered systemic hemodynamics. Following
the administration of indomethacin, RVR was decreased and RBF was
increased in potassium-depleted rats. Similar results were obtained with
another cyclo-oxygenase inhibitor, meclofenamate, and with imidazole,
an inhibitor of thromboxane synthetase. Because neither angiotensin II
nor products of endoperoxide metabolism could alone account for the
increased renal vascular resistance of potassium depletion, studies were
performed in potassium-depleted rats treated with indomethacin plus
either saralasin or teprotide. In these potassium-depleted animals, renal
blood flow was restored to normal. In conclusion, the decrease in renal
blood flow and the increase in renal vascular resistance in potassium
depletion is mediated by angiotensin II and a product of prostaglandin
endoperoxide metabolism, most likely, thromboxane.
Mécanismes de Ia diminution du debit sanguin renal chez le rat éveillé
déplété en potassium. Bien que Ia depletion chronique en potassium sois
un problème clinique commun, les consequences hemodynamiques de
Ia depletion potassique chronique n'ont pas ete clairement definies.
Dans cette etude, nous avons evalue les consequences hémodyna-
miques de la depletion potassique chronique chez le rat eveille. Les rats
depletes en potassium avaient une diminution de Ia pression arterielle
moyenne due a une diminution des resistances vasculaires périphé-
riques. En plus de ces modifications hemodynamiques pénpheriques, le
debit sanguin renal (RBF) etait diminué chez les animaux depletes en
potassium. Cette diminution du debit sanguin renal etait due a l'aug-
mentation des resistances vasculaires rénales (RVR). L'activité rénine
plasmatique etant augmentee chez les animaux depletes en potassium,
nous avons recherche un role vasoconstricteur renal de l'angiotensine
II en utilisant deux antagonistes de l'angiotensine. Bien que l'adminis-
tration de saralasine aux rats depletes en potassium n'ait pas altere
l'hemodynamique pCriphCrique, les RVR étaient diminuees. Nous
avons obtenu des résultats identiques avec le teprotide, un inhibiteur de
l'enzyme de conversion. Les produits du metabolisme des endoperox-
ides pouvant entraIner une vasoconstriction rénale, nous avons recher-
ché une vasoconstriction rénale due aux prostaglandines et au throm-
boxane en employant des inhibiteurs du thromboxane, de Ia cyclo-
oxygenase et de la synthétase. Aucun de ces agents n'a modifie
l'hémodynamique périphérique. Aprés administration d'indometha-
cine, les RVR étaient diminuées et le RBF était augmente chez les rats
depletes en potassium. Des résultats identiques ont ete obtenus avec un
autre inhibiteur de Ia cyclo-oxygénase, le méclofénamate, et avec
l'imidazole, un inhibiteur de Ia thromboxane synthétase. Puisque ni
l'angiotensine II ni les produits du métabolisme des endopéroxides ne
pouvaient a eux seuls rendre compte de l'augmentation des resistances
vasculaires renales au cours de Ia depiCtion potassique, nous avons fait
des etudes chez des rats depletes en potassium, traites par l'indométha-
cine plus de Ia Saralasine ou du Teprotide. Chez les animaux depletes
en potassium, le debit sanguin renal est revenu a Ia normal. En
conclusion, la diminution du debit sanguin renal, et l'augmentation des
resistances vasculaires rénales au cours de la déplétion potassique sont
médiées par l'angiotensine II et par un produit du mCtabolisme des
endoperoxides, trés probablement le thromboxane.
Although the hemodynamic effects of alterations in serum
potassium have been extensively studied, most of these studies
have been performed on isolated perfused limbs or vessels from
normokalemic animals in which the perfusion solutions were
rendered hypokalemic. These studies have clearly demonstrat-
ed that acute hypokalemia results in vasoconstriction in muscle
[1, 2], the kidney [3], and isolated arteries [4, 5].
In contrast to the well described vasoconstriction which
accompanies acute hypokalemia, the hemodynamic conse-
quences of chronic potassium depletion have not been defined
clearly. In this regard, in a number of older studies, potassium
depletion was found to lower the mean arterial pressure of
animals with experimental hypertension [6—8]. Although it is
likely that this effect was mediated by a decrease in systemic
vascular resistance rather than by a decrease in cardiac output,
no hemodynamics studies were performed to distinguish these
two possibilities. Moreover, although recent animal studies
have confirmed the observation that chronic potassium deple-
tion markedly affects systemic hemodynamics, the nature of the
alterations in hemodynamics differ between these two studies.
Whereas Abbrecht [9] found that potassium depletion resulted
in a decrease in cardiac output and an increase in systemic
vascular resistance, both Bahler and Rakita [10] and Galvez et
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a! [11], noted a marked decrease in systemic vascular resistance
and an increase in cardiac output.
Not only are the systemic hemodynamic effects of chronic
potassium depletion poorly defined, but, in addition, the effects
of potassium depletion on renal hemodynamics have not been
clearly delineated. Potassium depletion has been reported to
decrease RBF in some [9, 12, 13] but not all studies [11]. The
failure to affect RBF is rather surprising in view of the fact that
potassium depletion not only alters systemic hemodynamics but
also has been found to be associated with an increase in activity
of two hormonal systems which may cause an increase in renal
vascular resistance: angiotensin II [14, 15] and thromboxane A2
[16].
The purposes of the present study were to define the conse-
quences of chronic potassium depletion on both systemic and
renal hemodynamics and to determine the roles of angiotensin
and prostaglandins in the control of renal blood flow (RBF) in
the potassium-depleted rat.
Methods
Studies were performed in male Sprague-Dawley rats weigh-
ing between 200 to 220 g at the initiation of the study. Animals
were fed either a potassium deficient diet (ICN Pharmaceuti-
cals, Cleveland, Ohio), supplemented with magnesium contain-
ing 4 mEq K/kg diet (potassium-depleted group) or a diet of
normal potassium content (210 mEq K/kg diet, potassium-
repleted group). The diet of normal potassium content was
prepared by supplementing the deficient diet with a combina-
tion of neutral potassium salts. Water and food intake were
allowed ad libitum. After 14 to 18 days, the animals were then
studied according to one of the following experimental
protocols:
Effect of dietary potassium restriction on plasma and tissue
potassium levels. To assess the effect of a decrease in the
dietary intake of potassium on plasma and tissue potassium
levels, plasma, renal, and skeletal muscle potassium were
measured in nine rats on a normal potassium diet and nine rats
on the potassium deficient diet. Following pentobarbital anes-
thesia, blood was obtained by aortic puncture and plasma
potassium was measured with an IL 343 flame photometer
(Instrumentation Laboratory, Inc., Lexington, Massachusetts).
Renal tissue and muscle potassium were determined by nitric
acid digestion. After drying the tissue to dry weight (130° C for
72 hr), the samples were ground to a fine powder and were
digested by boiling in 1 ml of nitric acid for 4 hr. The resulting
clear liquid was diluted to 25 ml with deionized water and the
potassium content was then determined.
Effect of potassium depletion on systemic and renal hemody-
namics. Cardiac Index (CI), systemic vascular resistance
(SVR), renal blood flow (RBF), and renal vascular resistance
(RVR) were determined in conscious rats by a radioactive
microsphere technique which was originally described by Hsu,
Kurtz, and Waidinger [171 and has been adapted for use in our
laboratory [18]. Eight potassium-depleted and 12 potassium-
repleted rats were used for study. Animals were prepared for
study with the use of ether (10 mm) and then allowed to recover
in restraining cages for 30 mm before any additional pharmaco-
logic maneuver was begun. Hemodynamic studies were per-
formed 60 mm later except in the imidazole groups which were
studied after 30 mm of infusion. Cannulation of the right jugular
vein, right carotid artery into the left ventricle, and femoral
artery was accomplished with tapered PE 350 tubing. Ventricu-
lar cannulation was confirmed by pressure wave tracing. During
surgery isotonic saline equivalent to 0.5% of the body weight
was infused to replace estimated fluid losses. The microspheres
used were 8.8 0.9 p. in diameter and were labeled with 85Sr
Mean arterial pressure (MAP) was monitored with pressure
transducer (4-329-I, Bell and Howell Company, Pasadena,
California) connected to a Gilson chart recorder.
Calculations were performed as follows:
CI (ml/min kg1) =
I CPM injected
Lfemoral blood CPM X femoral flow rate]
÷ (body wt)
SVR (mm Hg/rn! min kg') = MAP CI
RBF (ml/min . g1) =
F kidney CPM
Lfemoral blood CPM femoral flow rate]
— (kidney wt)
RVR (mm Hg/rn! min' g')
MAP ÷ (mean RBF per 2 kidneys).
Because animals on a potassium-deficient diet eat less food
and gain less weight than do animals on a potassiurn-repleted
diet [14, 19], studies were performed in four additional animals
maintained on a potassiurn-repleted diet but whose food intake
was limited to that of pair fed animals on a potassium-deficient
diet. Moreover, to determine whether or not the alterations in
hemodynarnics in potassium-depleted rats (vida infra) could
have been caused by a decrease in external sodium balance in
potassium-depleted rats, plasma volume was determined by the
'251-albumin distribution space technique which was described
by Flamenbaurn et a! [201 and has been adapted for use in our
laboratory [18]. Six potassium-depleted rats were compared to
six potassiurn-repleted animals. In these groups water and food
were allowed ad libitum.
Role of angiotensin in potassium-depleted rats. Effect of
potassium depletion on plasma renin activity. To assess the
effect of a decrease in the dietary intake of potassium on
circulating levels of renin activity, plasma renin activity was
measured in potassium-repleted (8) and in potassium-depleted
(8) rats. In these rats, blood was obtained as free flowing blood
issuing from the trunk of guillotined animals. Blood was collect-
ed in chilled tubes containing sodium EDTA and was centri-
fuged within 15 mm at 0° C. The plasma was stored at —20° C
and subsequently assayed for renin activity within 5 days after
collection.
Effect of angiotensin antagonism in potassium-depleted rats.
To determine the significance of angiotensin in potassium
depletion, chemically different inhibitors of the renin-angioten-
sin axis were administered to potassium-depleted animals.
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In the first group of studies, saralasin (5 .tg/kg/min) was
infused intravenously for 60 mm following recovery from
anesthesia. Systemic and renal hemodynamics were then deter-
mined. This dose of saralasin was found in preliminary studies
to prevent completely the pressor response to 25 ng of exoge-
nous angiotensin II. Eight potassium-depleted rats given sarala-
sin were compared to six potassium-depleted rats given a
comparable volume of 0.2 N sodium chloride, the carrier vehicle
for saralasin, and to seven potassium-repleted rats given
saralasin.
For the second group of studies, teprotide (SQ 20,881, 3
mg/kg) was injected intravenously immediately following recov-
ery from anesthesia and, 60 mm later, hemodynamics were
determined. In preliminary studies, this dose of teprotide was
found to prevent completely the pressor response to 50 ng of
exogenous angiotensin I. Seven potassium-depleted rats given
teprotide were compared to six potassium-depleted rats given a
comparable volume of 0.2 N sodium chloride and to seven
potassium-repleted rats given teprotide.
Role of prostaglandins and thromboxane in the potassium-
depleted rats. Effect of potassium depletion on urinary PGE2
excretion. To determine the effect of a decrease in the dietary
intake of potassium on urinary prostaglandin excretion, urinary
PGE2 excretion was measured in 12 potassium-repleted and in
12 potassium-depleted animals. In other animals (12 potassium-
repleted, 12 potassium-depleted), indomethacin (5 mg/kg) or
meclofenamate (3 mg/kg) was administered intraperitoneally
and, to confirm the degree of cyclo-oxygenase blockade, uri-
nary PGE2 excretion was measured over the ensuing 8 hr. For
these studies, animals were placed in metabolic cages (Hoeltge
Company, Cincinnati, Ohio), which allowed for separation of
urine and feces. After allowing 2 days for equilibration to the
cages, the animals were injected with either drug or buffer;
urine samples were collected between 8 A.M. and 4 P.M. into
glass tubes containing 500 1.d of a 20% sodium azide solution.
After carefully measuring the volume, the urine samples were
stored at —20° C and subsequently assayed for PGE2 by a
modification of the procedure of Dray, Carbonnel, and Maclouf
[211.
Effect of the inhibition of prostaglandin and thromboxane
formation in potassium-depleted rats. To determine the signifi-
cance of prostaglandins in potassium depletion, chemically
different inhibitors of prostaglandin cyclo-oxygenase were ad-
ministered to potassium-depleted animals.
In the first group of studies, indomethacin was administered
intraperitoneally 2 hr prior to surgery. Eight potassium-deplet-
ed rats given indomethacin were compared to seven potassium-
depleted rats given a comparable volume of phosphate buffer,
the carrier vehicle for indomethacin. In addition, seven potassi-
um-repleted rats given indomethacin were compared to six
potassium-repleted rats given buffer. Hemodynamics were
measured 60 mm after recovery from anesthesia.
For the second group of studies, sodium meclofenamate was
administered intraperitoneally 2 hr prior to surgery. Nine
potassium-depleted rats given meclofenamate were compared
to eight potassium-depleted rats given a comparable volume of
carbonate buffer, the carrier vehicle for meclofenamate. In
addition, six potassium-repleted rats given meclofenamate were
compared to six potassium-repleted rats given buffer. Hemody-
namics were measured 60 mm after recovery from anesthesia.
Because both indomethacin and meclofenamate are cyclo-
oxygenase inhibitors which prevent the synthesis of both vaso-
dilator prostaglandins (PGE2 and PGI2) and vasoconstrictor
prostaglandins (thromboxane, TXA2) and because TX forma-
tion by both renal papillary and cortical slices has recently been
shown to be increased in potassium-depleted rats [161, a third
group of animals was studied using the specific thromboxane
synthetase inhibitor imidazole [221. For these studies imidazole
was prepared as a 0.4 M solution in 0.9% sodium chloride which
had been adjusted to pH 7.5 with hydrochloric acid. Following
recovery from anesthesia, imidazole was administered at a rate
of 2.04 mg/kg'min (0.03 mmoles/kg'min) intravenously to
eight potassium-depleted rats and six potassium-repleted rats.
Six potassium-repleted and six potassium-depleted rats re-
ceived a comparable volume of 0.9% sodium chloride. Hemo-
dynamic studies were performed 30 mm later.
Effect of both angiotensin antagonism and thromboxane
inhibition in potassium depletion. To further determine the
importance of products of prostaglandin endoperoxide metabo-
lism as mediators of renal vasoconstriction in potassium deple-
tion (vida infra), studies were performed in potassium-depleted
rats treated with indomethacin and either saralasin or teprotide.
For these studies potassium-repleted rats [13] and potassium-
depleted rats [121 were treated with indomethacin 2 hr prior to
surgery, and following recovery from anesthesia, either sarala-
sin (5 p1kg/mm IV) or teprotide (3 mg/kg IV) was administered.
Hemodynamics were assessed 1 hr later. In preliminary studies
these doses of angiotensin inhibitors had been found to prevent
the pressor responses to angiotensin II and I, respectively.
Plasma renin activity [23] was determined by radio-
immunoassay. Statistical analyses were performed using either
the unpaired Student's t test or one-way analysis of variance
with Scheffes's test for multiple comparisons [24]. P < 0.05 was
considered significant. Data are expressed as the mean SEM.
Resu!ts
Effect of dietary potassium restriction on plasma and tissue
potassium levels. After 2 weeks of dietary potassium deficien-
cy, plasma potassium was reduced from 4.01 0.15 to 2.26
0.16 mEq/liter, P < 0.001. Kidney potassium was reduced from
335.1 4.2 to 287.1 7.8 mEq/kg dry weight, P < 0.001 and
muscle potassium was reduced from 377.6 6.8 to 295.6 3.3
mEq/kg dry weight, P < 0.001.
Effect of potassium depletion on systemic and renal hemody-
namics. Table I shows the hemodynamic consequences of 14 to
17 days of dietary potassium deficiency in the conscious rat.
There were marked changes in both systemic and renal hemo-
dynamics in potassium-depleted animals. MAP was decreased
by 9% in potassium-depleted rats, The decrease in MAP was
mediated by a 25% decrease in SVR because CI increased
approximately 20%. In association with these changes in sys-
temic hemodynamics, there was a marked deterioration in renal
hemodynamics. RBF was decreased by 40%. Although this
decrease in RBF was associated with a decrease in MAP in
potassium-depleted animals (119.6 to 108.1 mm Hg), this level
of MAP is within the autoregulatory range of the rat [25]. Table
I demonstrates that rather than the expected decrease in RVR
which would have been expected in normal rats with this slight
decrease in MAP, RVR was increased by more than 60% in
potassium-depleted animals. Thus, the decrease in RBF in
760 Linas and Dickmann
Table 1. The effect of potassium depletion on systemic and renal hemodynamics in the conscious rat
RBF
ml/min-g
RVR
mm Hg/mlmin'g
MAP
mm Hg
CI
nlIminkg
SVR
mm Hg/m1minkg
Potassium-repleted 6.64 17.8 119.6 338 0.37(l2)
Potassium-depleted 3.60 29.6 108.1 408 0.27
(8)a
P value 0.001 0.001 0.01 0.05 0.01
Abbreviations are: RBF, renal blood flow; RVR, renal vascular resistance; MAP, mean arterial pressure; CI, cardiac index; SVR, systemic
vascular resistance.
The number in parenthesis refers to the number of rats.
potassium-depleted rats was mediated by an increase in RVR.
Furthermore, although rats maintained on a potassium deficient
diet ate less than rats maintained on the control diet [14, 19], the
alteration in hemodynamics in potassium deficient rats was not
the consequence of a decrease in food intake, because neither
systemic nor renal hemodynamics were altered in animals
maintained on a potassium-repleted diet, but whose food intake
was limited to that of pair fed animals on a potassium deficient
diet. Moreover, as has been shown by Galvez et al [11], the
alterations in hemodynamics were not the result of a decrease in
external sodium balance in potassium-depleted rats as plasma
volume was increased in these animals: 4.08 0.2 vs. 3.50
0.1 ml/100 g of body wt, P < 0.05. We next attempted to
determine the factors responsible for the increased RVR of
potassium-depleted animals.
Role of angiotensin in potassium-depleted rats. Because
PRA was increased in potassium-depleted rats (8.5 0.9 vs. 2.2
0.7 ngAI/mlhr, P < 0.005), we evaluated the role of
angiotensin as a renal vasoconstrictor in potassium depletion
with agents which prevent the synthesis (teprotide) or action
(saralasin) of angiotensin II.
The administration of these dissimilar angiotension antago-
nists did not alter significantly MAP, CI, or SVR in either
potassium-repleted or -depleted animals.
In contrast to the lack of an effect on systemic hemodynam-
ics, the administration of angiotensin antagonists led to marked
changes in renal hemodynamics in potassium-depleted animals.
Figures 1 and 2 demonstrate the fact that the administration of
either saralasin or teprotide resulted in a significant decrease in
renal vascular resistance and a significant increase in RBF in
potassium-depleted animals. Of note is the fact that although
RBF improved in angiotensin-antagonized rats, it did not reach
the level of potassium-repleted rats treated with these drugs.
Role ofprostaglandins and thromboxane in potassium deple-
tion. Because TX production by renal papillary slices has been
reported to be increased in potassium depletion [16], we evalu-
ated the role of TX as a renal vasoconstrictor in potassium
depletion by using agents that prevent the synthesis of PG and
TX (indomethacin and meclofenamate) and an agent which
selectively prevents the synthesis of TX (imidazole) [22]. As
has been reported [26], urinary PGE2 excretion was not altered
in potassium-depleted animals: potassium-repleted 11.2 1.8
ngI8 hr; potassium-depleted 10.0 1.6 ng/8 hr. Moreover, the
doses of cyclo-oxygenase inhibitors used in these studies sup-
pressed urinary PGE2 excretion to approximately 20% of basal
values in both potassium-repleted rats (indomethacin 2.4 0.4
ngI8 hr; meclofenamate 2.0 1.1 ngI8 hr) and in potassium-
_____ —
H P<.051
______
Fig. 1. The effect of saralasin on renal hemodynamics in potassium-
repleted and -depleted rats. P values refer to comparisons between
adjacent groups; that is, potassium-depleted versus -depleted plus
saralasin and potassium-depleted plus saralasin versus potassium-
repleted plus saralasin.
depleted rats (indomethacin 2.3 0.3 ng/8 hr; meclofenamate
1.8 1.3 ng/8 hr). Although TX production was not assessed, it
is likely that TXA2 levels were also decreased by these cyclo-
oxygenase inhibitors because TXA2, like PGE2, depends on the
formation of PG endoperoxides for its synthesis [22].
The administration of these cyclo-oxygenase inhibitors did
not alter significantly either systemic or renal hemodynamics in
potassium-repleted animals.
In contrast to the lack of an effect in potassium-repleted
animals, the administration of these cyclo-oxygenase inhibitors
led to marked changes in hemodynamics in potassium-depleted
animals. Table 2 demonstrates that cyclo-oxygenase inhibition
did not alter systemic hemodynamics. Figures 3 and 4, howev-
er, demonstrate that the administration of either indomethacin
or meclofenamate resulted in a significant decrease in renal
vascular resistance and a significant increase in renal blood flow
in potassium-depleted animals. The increase in renal blood
flow, however, did not reach the level of potassium-repleted
animals treated with these inhibitors.
P< .01
P<.01
0
8
40
a,
20
H 10
-I-
EJ K-depleted
K-depleted plus saralasin
K-repleted plus saralasin
P<.01
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El K-depleted
K-depleted plus teprotide
K-repleted plus teprotide
p
<.05,
Because PG inhibition may be associated with a decrease in
PRA [27—29], PRA after PG inhibition was measured to deter-
mine whether or not the vasodilatory effect of PG inhibition was
due to a decrease in PRA. Following PG inhibition with either
indomethacin (9.2 0.9 ng/AI.hr) or meclofenamate (8.3 1
ngIAFhr), PRA was the same as in potassium-depleted ani-
mals treated with buffer (8.5 0.9 ngAI/mlhr'). Thus, the
beneficial effects of endoperoxide inhibitors on renal hemody-
namics were independent of changes in PRA because RVR
decreased in the presence of these drugs despite the continued
elevation of PRA.
In the absence of changes in either systemic hemodynamics
or in PRA, the results suggested that the beneficial effect of
cyclo-oxygenase inhibition was due to the removal of a vaso-
constrictor PG generated from PG endoperoxides. Because
TXA2 formation by renal papillary slices has been reported to
be increased in potassium-depletion [16]. the thromboxane
synthetase inhibitor imidazole was administered to potassium-
depleted animals. Table 3 demonstrates the fact that the amount
of imidazole used in this study did not alter either systemic or
renal hemodynamic in potassium-repleted animals. In contrast,
in the absence of changes in systemic hemodynamics, the
administration of imidazole led to a decrease in RVR and an
increase in RBF in potassium-depleted animals. Furthermore,
the changes in renal hemodynamics were comparable to the
changes produced by the two cyclo-oxygenase inhibitors and
suggest, therefore, that the salutory effect of the cyclo-oxygen-
ase inhibitors was due to their ability to prevent the formation
of the vasoconstrictor TXA2.
Effect of angiotensin antagonism and prostaglandin inhibi-
tion in potassium depletion. Because both angiotensin antago-
nism and prostaglandin inhibition only partially restored renal
hemodynamics in potassium-depleted rats, we performed stud-
Potassium-depleted + 105.3 385 0.28
Indomethacin
(8)a
Potassium-depleted 106.1 407 0.26
(7)a
P value NS NS NS
Potassium-depleted + 110.8 409 0.28
Meclofenamate
(9)a
Potassium-depleted 105.5 396 0.27
(8)a
P value NS NS NS
ies in which both hormone systems were inhibited. The results
of these studies are shown in Table 4. When saralasin or
teprotide were administered to potassium-depleted rats in
which endoperoxide metabolism had been inhibited by indo-
methacin, RBF was restored completely to values obtained in
potassium-repleted animals. Moreover, this normalization of
RBF occurred despite the fact that MAP was significantly less
in potassium-depleted animals. Thus, the decreased RBF of
potassium depletion was not simply a manifestation of a de-
creased MAP, but rather a manifestation of an inappropriately
high RVR caused by both angiotensin II and a vasoconstrictor
prostaglandin.
Discussion
Although it has been known for many years that chronic
potassium depletion causes a decrease in MAP [6—8], the
hemodynamic factors causing this effect have not been studied
extensively. The results of the present study clearly demon-
strate that dietary potassium depletion results in marked alter-
ations in both systemic and renal hemodynamics in the rat.
The major systemic effect of potassium depletion was a
marked decrease in SVR which resulted in a decrease in MAP
because CI did not increase to a level sufficient to offset the
decrease in SVR. While other investigators have demonstrated
a comparable decrease in SVR in potassium depletion [10, 11],
this decrease has not been a universal finding [9] and may
depend on the methods or duration of potassium depletion.
Moreover, the decrease in SVR in chronic potassium-depleted
rats contrasts with the results of studies in which vessels or
limbs from potassium-repleted animals are perfused with hypo-
kalemic solutions. Many such studies have documented that
acute hypokalemia results in vasoconstriction in potassium-
repleted preparations [1—5]. The present study, therefore, un-
derscores the importance of the duration of potassium depletion
on systemic hemodynamics in potassium deficient rats.
In contrast to the vasodilation of the peripheral circulation,
potassium depletion led to an increase in renal vascular resist-
ance which resulted in a decrease in RBF. Because potassium
depletion per se appeared to cause systemic vasodilatation, we
attempted to identify the factors which resulted in renal
vasoconstriction.
8
6 p<.01
4 P< .01
Table 2. The effect of prostaglandin inhibition on systemic
hemodynamics in potassium depletion
2
0
MAP CI SVR
mm Hg ml/minkg mm Hg/mlmin kga
0)
a,
C.).—
U,)
. .
11—
40
30
P <.01
20
10
Abbreviations are listed in Table 1.
a The number in parenthesis refers to the number of rats.
Fig. 2. The effect of teprotide on renal hemodynamics in potassium-
repleted and potassium-depleted rats.
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Table 3. The effect of thromboxane inhibition with imidazole in potassium depletion
RBF
mlIming'
RVR
mm HgImlmin'g'
MAP
mm Hg
CI
,nl/minkg
SVR
mm HgImlminkg
Potassium-repleted 6.8 17.7 118 319 0.37
+ Imidazole
(6)a
Potassium-repleted 6.6 18.1 119 312 0.38
(6)a
P value NS NS NS NS NS
Potassium-depleted 4.8 24.6 112 403 0.277
+ Imidazole +2.8
(8)
Potassium-depleted 3.4 32.1 108 410 0.26
(6)a
P value 0.02 0.01 NS NS NS
Abbreviations are listed in Table 1.
The number in parenthesis refers to the number of rats.
P<.05
Although potassium deficient rats eat less and gain less
weight than control rats [14, 19], it is unlikely that the decrease
in food intake or a negative external sodium balance accounts
for these changes in hemodynamics. In this regard, hemody-
namics were not altered by limiting food intake in control rats.
Moreover, rats on a potassium deficient diet have been shown
to be in a more positive sodium balance than rats on an
unrestricted potassium diet [14]; this is reflected by the fact that
these animals have an increase in plasma volume and an
increase in CI (Table 1).
As has been observed previously [14, 15], PRA was found to
be increased in potassium-depleted animals. Because angioten-
sin II is a potent renal vasoconstrictor, the role of All in
potassium depletion was evaluated by utilizing two antagonists
of the renin-angiotensin system. Although the administration of
angiotensin antagonists did not alter systemic hemodynamics in
potassium-depleted rats, angiotensin antagonism resulted in a
substantial decrease in RVR, which resulted in a significant
increase in RBF in potassium-depleted animals. These results
suggest that a major contributing factor to the increase in RVR
and the decrease in RBF of potassium depletion is angiotensin
II. Moreover, because the RVR of potassium deplete angioten-
sin antagonized rats remained significantly greater than potassi-
um replete animals, the results also suggest the presence of
another renal vasoconstrictor in the potassium deplete rat.
Although the role of the prostaglandin system has attracted
considerable interest with regard to the control of the renal
circulation during pathological states, its role in the control of
t: K-depleted
K-depleted plus indomethacin
K-repleted plus indomethacin
p<.01
p<.o14
2
0
J K-depleted
K-depleted plus meclofenamate ,
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P < .01
P< .01
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-
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Fig. 3. The effect of indomethacin on renal hemodynamics in potassi-
um-repleted and potassium-depleted rats.
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Fig. 4. The effect of sodium meclofena,nate on renal hemodvnamics in
potassium-repleted and potassium-depleted rats.
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Table 4. The effect of prostaglandin inhibition with indomethacin and angiotensin antagonism with saralasin or teprotide in potassium depletion
Abbreviations are listed in Table I
The number in parenthesis refers to the number of rats.
the renal circulation during potassium depletion has not been
explored. In the present study, inhibition of cyclo-oxygenase
with either indomethacin or meclofenamate resulted in a de-
crease in RVR and an increase in RBF in potassium-depleted
animals (Figs. 3 and 4). Because PGE2 may cause renal
vasoconstriction in the rat [30, 311, our results could be
interpreted to mean that the salutory effect of these agents was
related to the removal of PGE2, a renal vasoconstrictor, or to a
prostaglandin independent effect of these drugs. There are
several reasons why these interpretations do not seem likely:
First, despite comparable levels of urinary PGE2 excretion,
cyclo-oxygenase inhibition did not result in any changes in renal
hemodynamics in potassium-depleted rats (Figs. 3 and 4).
Second, the salutory effect of cyclo-oxygenase inhibition was
demonstrated with two chemically dissimilar enzyme inhibi-
tors. Third, urinary PGE2 excretion was not found to be
increased in the potassium-depleted rat either in the present
study or in an earlier study by Hood and Dunn [26].
Because prostaglandin inhibition is often associated with a
decrease in plasma renin activity [27—29], cyclo-oxygenase
inhibition could have resulted in an improvement in renal
hemodynamics through a decrease in renal renin production.
This mechanism seems unlikely because plasma renin activity
was not altered by cyclo-oxygenase inhibition in the present
study. Although Galvez et al [11] have shown that cyclo-
oxygenase inhibition lowers plasma renin activity in the potassi-
um-depleted dog, urinary PGE2 excretion was increased mark-
edly in these animals while PGE2 excretion was not increased in
the potassium-depleted rat in the present study or the studies of
Hood and Dunn [26].
In view of recent studies of thromboxane, a vasoconstrictor
product of arachidonic acid metabolism, another explanation
for the beneficial effect of cyclo-oxygenase inhibition seems
plausible. Although thromboxane A2 is produced by the normal
kidney [32], its production is increased markedly in several
pathological states such as ureteral obstruction [33] and renal
vein constriction [34]. Moreover, Beck and Shaw [161 have
shown that renal papillary thromboxane production is increased
in potassium-depleted rats. Because thromboxanes are potent
vasoconstrictor substances, it seemed likely that the salutory
effect of cyclo-oxygenase inhibition may have been due to the
prevention of thromboxane formation by potassium deficient
animals. In support of this observation, when the thromboxane
synthetase inhibitor imidazole [22] was administered to potassi-
um-depleted animals, RVR was decreased and RBF was in-
creased to levels which were comparable to the levels obtained
after cyclo-oxygenase inhibition (Table 3, Figs. 3 and 4).
Although it is likely that the beneficial effect of imidazole was
caused by a decrease in thromboxane synthesis, other alterna-
tives are possible because the drug may have effects which are
independent of the prostaglandin-thromboxane system [35—38].
These nonspecific effects, however, are only observed when
the drug is given in quantities which are at least twice adminis-
tered in the present study [35, 36, 381.
Considered together, therefore, the results of these studies
utilizing two chemically dissimilar cyclo-oxygenase inhibitors
and a thromboxane synthetase inhibitor suggest that the benefi-
cial effect of these agents on RVR and RBF in the potassium-
depleted rat are the consequence of the prevention of the
enhanced thromboxane synthesis observed in potassium-de-
pleted kidneys.
Finally, because neither angiotensin antagonism nor PG
inhibition alone decreased RVR to levels sufficient to restore
RBF to normal potassium depletion, studies were performed in
which both angiotensin and prostaglandin were inhibited. Uti-
lizing indomethacin and either saralasin or teprotide, RBF was
restored to normal values (Table 4). The normalization of RBF
in potassium-depleted animals occurred despite a decreased
MAP, thereby confirming that the decreased RBF of potassium
depletion was not a manifestation of the decreased MAP, but
rather the consequence of an inappropriate increase in RVR
caused by angiotensin II and a product of prostaglandin endo-
peroxide metabolism.
In summary, chronic potassium depletion leads to marked
changes in both systemic and renal hemodynamics in the
potassium-depleted rat. There is a decrease in SVR which
results in a decrease in MAP. Despite this peripheral vasodilata-
tion, there is a marked increase in RVR which results in a
RBF
mlIming'
RVR
mm HgImlmin'g'
MAP
mm Hg
CI
ml/minkg'
SVR
mm Hg/mlmin'kg
Potassium-repleted 6.83 17.0 113.3 301 0.37
+ Indomethacin
Saralasin (6)a
Potassium-depleted 6.79 14.9 100 400 0.25
+ Indomethacin
Saralasin (6)
P value NS 0.02 0.001 0.001 0.01
Potassium-repleted 7.24 16.1 114.7 360 0.32
+ Indomethacin
Teprotide (7)a
Potassium-depleted 7.17 14.5 101 436 0.23
+ Indomethacin
Teprotide (6)a
P value NS 0.05 0.001 0.005 0.00!
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decrease in RBF. The increased RVR is caused by both
angiotensin II and a product of prostaglandin endoperoxide
metabolism because the combination of angiotensin antagonism
and prostaglandin inhibition results in the restoration of RBF to
normal values in potassium-depleted animals.
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